Journal article
Cognition and beta-amyloid in preclinical Alzheimer's disease: Data from the AIBL study
KE Pike, KA Ellis, VL Villemagne, N Good, G Chételat, D Ames, C Szoeke, SM Laws, G Verdile, RN Martins, CL Masters, CC Rowe
Neuropsychologia | Published : 2011
Abstract
The 'preclinical' phase of Alzheimer's disease is a future target for treatment, but additional research is essential to understand the relationship between β-amyloid burden and cognition during this time. We investigated this relationship using a large sample of apparently healthy older adults (N=177), which also enabled examination of whether the relationship differed according to age, gender, years of education, apolipoprotein E status, and the presence of subjective memory complaints. In addition to episodic memory, a range of cognitive measures (global cognition, semantic memory, visuospatial performance, and executive function) were examined. Participants were aged over 60 years with n..
View full abstractGrants
Funding Acknowledgements
Core funding for the study was provided by the Australian Commonwealth Scientific Industrial Research Organization (CSIRO) through the Australian Imaging, Biomarkers and Lifestyle flagship study of aging (AIBL), which was supplemented by "in kind" contributions from AIBL research partner organisations: University of Melbourne, Neurosciences Australia Ltd (NSA), Edith Cowan University (ECU), Mental Health Research Institute (MHRI), Alzheimer's Australia (AA), National Ageing Research Institute (NARI), Austin Health, University of WA (UWA), CogState Ltd., Macquarie University, Hollywood Private Hospital, and Sir Charles Gairdner Hospital. The funding source had no direct role in the design and conduct of the study; collection, management, analysis, and interpretation of the data, or preparation, review, and approval of the manuscript.